cyp3a4
cyp3a4: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: RIGEL PHARMACEUTICALS INC (RIGL)
Development Pipeline (1)
| Company | Phase |
|---|---|
| RIGEL PHARMACEUTICALS INC (RIGL) | Phase 4 |
Clinical Trials (1)
A Multi-center, Open-label, Drug-drug Interaction Study to Evaluate the Effect of Pralsetinib (Gavreto) on the Pharmacokinetics of CYP3A4, CYP2C8, and CYP2C9 Substrates, and Hormones Estradiol/Norethisterone Acetate in Patients With Advanced or Metastatic Solid Tumors
Frequently asked questions
Who is developing cyp3a4?
cyp3a4 is being developed by RIGEL PHARMACEUTICALS INC.
How many clinical trials involve cyp3a4?
BioSniper tracks 1 clinical trial involving cyp3a4.
Analyze RIGEL PHARMACEUTICALS INC & cyp3a4 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company